Cooperative Agreement UG3NS146009
Award Date 4/24/26
Completion Date 3/31/28
Dollars Obligated $2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Cambridge, MA 02140, USA
Similar Awards
- Federal Cooperative Agreement Award Summary The University of Southern California Department of Contracts and Grants received a $818,360 Cooperative Agreement from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2025, through May 31, 2029. The award supports the development of angiotensin AT2 receptor (AT2R) antagonists for treating neuropathic pain,...
- Federal Cooperative Agreement Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,024,374 Cooperative Agreement to the University of Washington on August 11, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the Equitable Primary Care for Pain Care (EquiP PC) project. The award supports a multi-site pragmatic three-arm cluster randomized controlled trial designed to improve equitable access to chronic pain management in primary...
- Federal Cooperative Agreement Summary Sparian Biosciences Inc. (doing business as Palion Therapeutics) received a $6.28 million Cooperative Agreement from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to support the clinical development of SBS-147, a first-in-class oral arylepoxamide agonist for pain management. The award, effective July 1, 2025 through June 30, 2027, funds the advancement of this non-opioid analgesic from preclinical and...
- Federal Cooperative Agreement Award Summary The University of Texas Health Science Center at Houston received a $2.08M Cooperative Agreement from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded August 11, 2025, with completion by July 31, 2027. The award supports the development of monoclonal antibody (mAb) inhibitors targeting matrix metalloproteinase-9 (MMP-9) to address diabetic neuropathic pain, a...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $407,113 to the University of California, Irvine on August 15, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support development of novel KV7 channel modulators for pain therapy. This R21 exploratory research grant, which concludes July 31, 2027, will establish an empirical foundation for developing therapies targeting...
- Federal Cooperative Agreement Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Seattle Children's Hospital a $4.64 million Cooperative Agreement on September 19, 2025, through the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a precision health model for pediatric chronic primary pain. This research initiative leverages the PEDSnet national pediatric learning health system to create a computable phenotype of chronic primary pain...
- Federal Cooperative Agreement Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University a $7.99 million Cooperative Agreement on September 1, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop negative allosteric modulators (NAMs) at the mu opioid receptor as potential therapeutics for opioid use disorder (OUD) and opioid overdose. The two-year research initiative, scheduled for completion on August 31, 2027, focuses on optimizing and...
- Federal Cooperative Agreement Summary The University of Pittsburgh received a $3.24M Cooperative Agreement from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 1, 2025, through August 31, 2027. This award supports the development and clinical evaluation of a fully implanted spinal cord stimulation (SCS) system designed to restore sensory sensation and alleviate phantom limb pain (PLP) in...
- Federal Cooperative Agreement Summary Sanford Burnham Prebys Medical Discovery Institute received a $3.86M Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279) on April 15, 2026, with completion targeted for March 31, 2028. The research deliverables focus on the preclinical development and characterization of SBI-553, a novel beta-arrestin 2 (ARRB2)-biased allosteric modulator of the...
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...